Redeye provides an initial take on Scandinavian ChemoTech’s Q1 2026 report. While sales (previously announced) came in below our expectations, operating costs were lower than anticipated. Overall, we view the report as solid; it demonstrates that the company is approaching break-even, which we believe could serve as the catalyst to align the share price with our base case.
LÄS MER
